Cargando…

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis

Only case reports and small clinical series report the effects of booster vaccination with BNT162b2 in patients with rheumatoid arthritis (RA). We studied 200 patients with RA in clinical remission evaluated with the DAS28. All patients were vaccinated for SARS CoV-2 with the BNT162b2 mRNA vaccine....

Descripción completa

Detalles Bibliográficos
Autores principales:	Benucci, Maurizio, Damiani, Arianna, Gobbi, Francesca Li, Lari, Barbara, Grossi, Valentina, Infantino, Maria, Manfredi, Mariangela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092040/ https://www.ncbi.nlm.nih.gov/pubmed/35543863 http://dx.doi.org/10.1007/s12026-022-09283-y

Ejemplares similares

Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab
por: Benucci, Maurizio, et al.
Publicado: (2021)

Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2018)

Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life
por: Benucci, Maurizio, et al.
Publicado: (2019)

The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
por: Benucci, Maurizio, et al.
Publicado: (2022)

Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?
por: Benucci, Maurizio, et al.
Publicado: (2022)

Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease
por: Malipiero, Giacomo, et al.
Publicado: (2021)

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
por: Benucci, Maurizio, et al.
Publicado: (2020)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
por: Benucci, Maurizio, et al.
Publicado: (2022)

Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies
por: Benucci, Maurizio, et al.
Publicado: (2020)

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
por: Benucci, Maurizio, et al.
Publicado: (2018)

Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174
por: Benucci, Maurizio, et al.
Publicado: (2023)

Old and new antirheumatic drugs for the treatment of COVID-19
por: Benucci, Maurizio, et al.
Publicado: (2020)

Médicaments rhumatologiques pour le traitement de l’infection par le COVID-19()
por: Benucci, Maurizio, et al.
Publicado: (2020)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab
por: Benucci, Maurizio, et al.
Publicado: (2016)

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2023)

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
por: Farroni, Chiara, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2022)

BNT162B2 MRNA BOOSTER VACCINE-RELATED PERICARDITIS: A CASE COMPLICATED BY PERICARDIAL AND PLEURAL EFFUSIONS
por: WHITE, ANESHA, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine
por: Infantino, Maria, et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
por: Paran, Yael, et al.
Publicado: (2021)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission
por: Bixio, Riccardo, et al.
Publicado: (2021)

Effect of BNT162b2 mRNA booster vaccination on VO(2) (max) in recreational athletes: A prospective cohort study
por: Miljoen, Hielko, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c009hrrsvbaf4q45dd85072jtq